Clinical and practical considerations in the pharmacologic management of narcolepsy

Sleep Medicine

Volumn 16, Issue 1, 2015, Pages 9-18

  Thorpy, Michael J ^a   Dauvilliers, Yves ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Cataplexy; Diagnosis; Excessive daytime sleepiness; Narcolepsy; Treatment

Indexed keywords

AMPHETAMINE; AMPHETAMINE PLUS DEXAMPHETAMINE; ARMODAFINIL; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; OXYBATE SODIUM; PITOLISANT; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; CENTRAL NERVOUS SYSTEM AGENTS;

CATAPLEXY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; HALLUCINATION; HUMAN; MEDICAL DECISION MAKING; NARCOLEPSY; NIGHT SLEEP; PREGNANCY OUTCOME; REVIEW; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT CHANGE; COMPLICATION; DRUG COMBINATION; PATIENT SELECTION; PSYCHOLOGY;

CENTRAL NERVOUS SYSTEM AGENTS; DRUG THERAPY, COMBINATION; HUMANS; NARCOLEPSY; PATIENT SELECTION;

EID: 84921438674     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2014.10.002     Document Type: Review

References (116)

1. Majid H., Hirshkowitz M. Therapeutics of narcolepsy. Sleep Med Clin 2010, 5:659-673.
2. Ohayon M.M. Epidemiology of narcolepsy. Narcolepsy and hypersomnia 2007, 125-132. Informa Healthcare, New York. C. Bassetti, M. Billiard, E. Mignot (Eds.).
3. Nishino S., Deguzman C., Yamadera W., Chiba S., Kanbayashi T. Neurochemistry and biomarkers of narcolepsy and other primary and secondary hypersomnias. Sleep Med Clin 2012, 7:233-248.
4. American Psychiatric Association (APA) Narcolepsy. Diagnostic and statistical manual of mental disorders, 5th ed. (DSM-5) 2013, 372-378. APA, Arlington, VA.
5. American Academy of Sleep Medicine International classification of sleep disorders - 3rd ed. (ICSD-3) 2014, American Academy of Sleep Medicine, Rochester, MN.
6. Singh A.K., Mahlios J., Mignot E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun 2013, 43:26-31.
7. De la Herran-Arita A.K., Garcia-Garcia F. Narcolepsy as an immune-mediated disease. Sleep Disord 2014, 2014:792687.
8. Espana R.A., Scammell T.E. Sleep neurobiology from a clinical perspective. Sleep 2011, 34:845-858.
9. Adamantidis A.R., Zhang F., Aravanis A.M., Deisseroth K., de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:420-424.
10. Aran A., Lin L., Nevsimalova S., Plazzi G., Hong S.C., Weiner K., et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009, 32:979-983.
11. Han F., Lin L., Warby S.C., Faraco J., Li J., Dong S.X., et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011, 70:410-417.
12. Partinen M., Saarenpaa-Heikkila O., Ilveskoski I., Hublin C., Linna M., Olsen P., et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 2012, 7:e33723.
13. Heier M.S., Gautvik K.M., Wannag E., Bronder K.H., Midtlyng E., Kamaleri Y., et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 2013, 14:867-871.
14. Miller E., Andrews N., Stellitano L., Stowe J., Winstone A.M., Shneerson J., et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013, 346:f794.
15. Szakacs A., Darin N., Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013, 80:1315-1321.
16. Nishino S., Ripley B., Overeem S., Nevsimalova S., Lammers G.J., Vankova J., et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001, 50:381-388.
17. Faraco J., Lin L., Kornum B.R., Kenny E.E., Trynka G., Einen M., et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 2013, 9:e1003270.
18. National Institute of Neurological Disorders and Stroke Narcolepsy fact sheet 2014, February 16. http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm#241213201.
19. Roth T., Dauvilliers Y., Mignot E., Montplaisir J., Paul J., Swick T., et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med 2013, 9:955-965.
20. Leu-Semenescu S., De Cock V.C., Le Masson V.D., Debs R., Lavault S., Roze E., et al. Hallucinations in narcolepsy with and without cataplexy: contrasts with Parkinson's disease. Sleep Med 2011, 12:497-504.
21. Wamsley E., Donjacour C.E., Scammell T.E., Lammers G.J., Stickgold R. Delusional confusion of dreaming and reality in narcolepsy. Sleep 2014, 37:419-422.
22. Pisko J., Pastorek L., Buskova J., Sonka K., Nevsimalova S. Nightmares in narcolepsy: underinvestigated symptom?. Sleep Med 2014, 15:967-972.
23. Nightingale S., Orgill J.C., Ebrahim I.O., de Lacy S.F., Agrawal S., Williams A.J. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med 2005, 6:253-258.
24. Frauscher B., Ehrmann L., Mitterling T., Gabelia D., Gschliesser V., Brandauer E., et al. Delayed diagnosis, range of severity and multiple sleep comorbidities: a clinical and polysomnographic analysis of 100 patients of the Innsbruck narcolepsy cohort. J Clin Sleep Med 2013, 9:805-812.
25. Dauvilliers Y., Montplaisir J., Molinari N., Carlander B., Ondze B., Besset A., et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57:2029-2033.
26. Okun M.L., Lin L., Pelin Z., Hong S., Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
27. Thorpy M.J., Krieger A.C. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med 2014, 15:502-507.
28. Rosenberg R., Kim A.Y. The AWAKEN survey: knowledge of narcolepsy among physicians and the general population. Postgrad Med 2014, 126:78-86.
29. Ohayon M.M. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med 2013, 14:488-492.
30. Jennum P., Ibsen R., Knudsen S., Kjellberg J. Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study. Sleep 2013, 36:835-840.
31. Black J., Reaven N.L., Funk S., McGaughey K., Ohayon M.M., Guilleminault C., et al. High rates of medical comorbidity in narcolepsy: findings from the burden of narcolepsy disease (BOND) study of 9,312 patients in the United States [abstract]. Sleep 2013, 36(Suppl.):A249.
32. Carter L.P., Acebo C., Kim A. Patients' journey to a narcolepsy diagnosis: a physician survey and retrospective chart review. Postgrad Med 2014, 126:216-224.
33. Kryger M.H., Walid R., Manfreda J. Diagnoses received by narcolepsy patients in the year prior to diagnosis by a sleep specialist. Sleep 2002, 25:36-41.
34. Pizza F., Franceschini C., Peltola H., Vandi S., Finotti E., Ingravallo F., et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 2013, 136:3787-3795.
35. Black J., Reaven N.L., Funk S., McGaughey K., Ohayon M.M., Guilleminault C., et al. The burden of narcolepsy disease (BOND) study: healthcare utilization and cost findings. Sleep Med 2014, 15:522-529.
36. Dodel R., Peter H., Spottke A., Noelker C., Althaus A., Siebert U., et al. Health-related quality of life in patients with narcolepsy. Sleep Med 2007, 8:733-741.
37. Jennum P., Ibsen R., Petersen E.R., Knudsen S., Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med 2012, 13:1086-1093.
38. Ingravallo F., Gnucci V., Pizza F., Vignatelli L., Govi A., Dormi A., et al. The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med 2012, 13:1293-1300.
39. Philip P., Sagaspe P., Lagarde E., Leger D., Ohayon M.M., Bioulac B., et al. Sleep disorders and accidental risk in a large group of regular registered highway drivers. Sleep Med 2010, 11:973-979.
40. Smolensky M.H., Di Milia L., Ohayon M.M., Philip P. Sleep disorders, medical conditions, and road accident risk. Accid Anal Prev 2011, 43:533-548.
41. Ohayon M.M., Black J., Lai C., Eller M., Guinta D., Chattacharyya A. Increased mortality in narcolepsy. Sleep 2014, 37:439-444.
42. Billiard M., Bassetti C., Dauvilliers Y., Dolenc-Groselj L., Lammers G.J., Mayer G., et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006, 13:1035-1048.
43. Morgenthaler T.I., Kapur V.K., Brown T., Swick T.J., Alessi C., Aurora R.N., et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30:1705-1711.
44. Xyrem (sodium oxybate) oral solution [prescribing information] 2014, Jazz Pharmaceuticals, Inc, Palo Alto, CA.
45. Nittur N., Konofal E., Dauvilliers Y., Franco P., Leu-Semenescu S., Cock V.C., et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med 2013, 14:30-36.
46. Mignot E.J. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurother 2012, 9:739-752.
47. Lopez R., Dauvilliers Y. Pharmacotherapy options for cataplexy. Expert Opin Pharmacother 2013, 14:895-903.
48. Dauvilliers Y., Bassetti C., Lammers G.J., Arnulf I., Mayer G., Rodenbeck A., et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 2013, 12:1068-1075.
49. Black J., Swick T., Feldman N., Doekel R. Jr, Khayrallah M., Bream G., etal. Efficacy and safety of oral ADX-N05 for the treatment of excessive daytime sleepiness in adults with narcolepsy: results of a randomized, double-blind, placebo-controlled trial [abstract]. Presented at: 28th Annual Meeting of the Associated Professional Sleep Societies (SLEEP); May 31-June 4, 2014; Minneapolis, MN. Abstract LBA4; 2014.
50. Bogan R.K., Feldman N.T., Lankford D.A., Khayrallah M.A. A double-blind placebo-controlled randomized crossover study of the efficacy and safety of ADX-N05 for the treatment of excessive daytime sleepiness in adult subjects with narcolepsy [abstract]. Sleep 2013, 36(Suppl.):A257.
51. Arias-Carrion O., Murillo-Rodriguez E. Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats. PLoS ONE 2014, 9:e95342.
52. Weinhold S.L., Seeck-Hirschner M., Nowak A., Hallschmid M., Goder R., Baier P.C. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 2014, 262:8-13.
53. Overeem S., Reading P., Bassetti C.L. Narcolepsy. Sleep Med Clin 2012, 7:263-281.
54. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 2008, 17:459-474.
55. Provigil (modafinil) tablets [prescribing information] 2010, Cephalon, Inc, Frazer, PA.
56. Nuvigil (armodafinil) tablets [prescribing information] 2010, Cephalon, Inc, Frazer, PA.
57. Vendrame M., Havaligi N., Matadeen-Ali C., Adams R., Kothare S.V. Narcolepsy in children: a single-center clinical experience. Pediatr Neurol 2008, 38:314-320.
58. Aran A., Einen M., Lin L., Plazzi G., Nishino S., Mignot E. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. Sleep 2010, 33:1457-1464.
59. Lecendreux M., Bruni O., Franco P., Gringras P., Konofal E., Nevsimalova S., et al. Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res 2012, 21:481-483.
60. Dauvilliers Y., Jaussent I., Krams B., Scholz S., Lado S., Levy P., et al. Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS ONE 2012, 7:e38977.
61. Grimaldi D., Silvani A., Benarroch E.E., Cortelli P. Orexin/hypocretin system and autonomic control: new insights and clinical correlations. Neurology 2014, 82:271-278.
62. American Geriatrics Society 2012 Beers Criteria Update Expert Panel American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012, 60:616-631.
63. Schwartz J.R., Nelson M.T., Schwartz E.R., Hughes R.J. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 2004, 27:74-79.
64. Martinez-Rodriguez J., Iranzo A., Santamaria J., Genis D., Molins A., Silva Y., et al. Status cataplecticus induced by abrupt withdrawal of clomipramine [Article in Spanish]. Neurologia 2002, 17:113-116.
65. Thorpy M.J., Schwartz J.R., Kovacevic-Ristanovic R., Hayduk R. Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies. Psychopharmacology (Berl) 2003, 167:380-385.
66. Auger R.R., Goodman S.H., Silber M.H., Krahn L.E., Pankratz V.S., Slocumb N.L. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep 2005, 28:667-672.
67. Bayard S., Langenier M.C., Dauvilliers Y. Effect of psychostimulants on impulsivity and risk taking in narcolepsy with cataplexy. Sleep 2013, 36:1335-1340.
68. Bayard S., Dauvilliers Y.A. Reward-based behaviors and emotional processing in human with narcolepsy-cataplexy. Front Behav Neurosci 2013, 7:50.
69. Tsujino N., Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci 2013, 7:28.
70. Vignatelli L., D'Alessandro R., Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database Syst Rev 2008, (1). CD003724.
71. Frey J., Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 1994, 44:707-709.
72. Izzi F., Placidi F., Marciani M.G., Zannino S., Torelli F., Corte F., et al. Effective treatment of narcolepsy-cataplexy with duloxetine: a report of three cases [letter]. Sleep Med 2009, 10:153-154.
73. Moller L.R., Ostergaard J.R. Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol 2009, 19:197-201.
74. Ju Y.E., Larson-Prior L., Duntley S. Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants. Sleep Med 2011, 12:278-283.
75. Drug-induced restless legs syndrome. Prescrire Int 2010, 19:164-165.
76. Black J., Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006, 29:939-946.
77. Zvosec D.L., Smith S.W., Porrata T., Strobl A.Q., Dyer J.E. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011, 29:319-332.
78. Wang Y.G., Swick T.J., Carter L.P., Thorpy M.J., Benowitz N.L. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009, 5:365-371.
79. Poryazova R., Tartarotti S., Khatami R., Baumann C.R., Valko P., Kallweit U., et al. Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience. Eur Neurol 2011, 65:175-182.
80. Fronczek R., Middelkoop H.A., van Dijk J.G., Lammers G.J. Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the sustained attention to response task (SART). Sleep 2006, 29:187-191.
81. Johns M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991, 14:540-545.
82. Hays R.D., Morales L.S. The RAND-36 measure of health-related quality of life. Ann Med 2001, 33:350-357.
83. Weaver T.E., Laizner A.M., Evans L.K., Maislin G., Chugh D.K., Lyon K., et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997, 20:835-843.
84. Bastien C.H., Vallieres A., Morin C.M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001, 2:297-307.
85. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
86. Ware J.E., Kosinski M., Keller S.D. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233.
87. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy (New York) 1990, 16:199-208. The EuroQol Group.
88. Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606-613.
89. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
90. Dauvilliers Y., Lopez R., Ohayon M., Bayard S. Hypersomnia and depressive symptoms: methodological and clinical aspects. BMC Med 2013, 11:78.
91. Liu X., Buysse D.J. Sleep and youth suicidal behavior: a neglected field. Curr Opin Psychiatry 2006, 19:288-293.
92. Goldstein T.R., Bridge J.A., Brent D.A. Sleep disturbance preceding completed suicide in adolescents. J Consult Clin Psychol 2008, 76:84-91.
93. Ohayon M.M. A longitudinal study of 322 individuals with narcolepsy [abstract]. Ann Neurol 2012, 72(Suppl. S16):52.
94. Posner K., Brown G.K., Stanley B., Brent D.A., Yershova K.V., Oquendo M.A., et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011, 168:1266-1277.
95. Engel A., Helfrich J., Manderscheid N., Musholt P.B., Forst T., Pfutzner A., et al. Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index?. Neuropsychiatr Dis Treat 2011, 7:351-356.
96. Beitinger P.A., Fulda S., Dalal M.A., Wehrle R., Keckeis M., Wetter T.C., et al. Glucose tolerance in patients with narcolepsy. Sleep 2012, 35:231-236.
97. Donjacour C.E.H.M., Aziz N.A., Overeem S., Kalsbeek A., Pijl H., Lammers G.J. Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. Sleep 2014, 37:795-801.
98. Abril B., Carlander B., Touchon J., Dauvilliers Y. Restless legs syndrome in narcolepsy: a side effect of sodium oxybate?. Sleep Med 2007, 8:181-183.
99. Plazzi G., Ferri R., Franceschini C., Vandi S., Detto S., Pizza F., et al. Periodic leg movements during sleep in narcoleptic patients with or without restless legs syndrome. J Sleep Res 2012, 21:155-162.
100. Pizza F., Tartarotti S., Poryazova R., Baumann C.R., Bassetti C.L. Sleep-disordered breathing and periodic limb movements in narcolepsy with cataplexy: a systematic analysis of 35 consecutive patients. Eur Neurol 2013, 70:22-26.
101. Dauvilliers Y., Pennestri M.H., Petit D., Dang-Vu T., Lavigne G., Montplaisir J. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res 2007, 16:333-339.
102. Bahammam A. Periodic leg movements in narcolepsy patients: impact on sleep architecture. Acta Neurol Scand 2007, 115:351-355.
103. Jambhekar S.K., Com G., Jones E., Jackson R., Castro M.M., Knight F., et al. Periodic limb movements during sleep in children with narcolepsy. J Clin Sleep Med 2011, 7:597-601.
104. Bedard M.A., Montplaisir J., Godbout R., Lapierre O. Nocturnal gamma-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol 1989, 12:29-36.
105. Billiard M. REM sleep behavior disorder and narcolepsy. CNS Neurol Disord Drug Targets 2009, 8:264-270.
106. Dahmen N., Bierbrauer J., Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 2001, 251:85-89.
107. Poli F., Pizza F., Mignot E., Ferri R., Pagotto U., Taheri S., et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep 2013, 36:175-181.
108. Kotagal S., Krahn L.E., Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med 2004, 5:147-150.
109. Sansa G., Iranzo A., Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med 2010, 11:93-95.
110. Feldman N.T. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath 2010, 14:77-79.
111. Husain A.M., Ristanovic R.K., Bogan R.K. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med 2009, 10:661-663.
112. Thorpy M., Zhao C.G., Dauvilliers Y. Management of narcolepsy during pregnancy. Sleep Med 2013, 14:367-376.
113. Maurovich-Horvat E., Kemlink D., Hogl B., Frauscher B., Ehrmann L., Geisler P., et al. Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies. J Sleep Res 2013, 22:496-512.
114. Krahn L.E., Martin K.A., Silber M.H. Narcoleptic patients' perceptions of nicotine [letter]. J Clin Sleep Med 2009, 5:390.
115. Ebben M.R., Krieger A.C. Narcolepsy with cataplexy masked by the use of nicotine. J Clin Sleep Med 2012, 8:195-196.
116. Corrigall W.A. Hypocretin mechanisms in nicotine addiction: evidence and speculation. Psychopharmacology (Berl) 2009, 206:23-37.